Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens

Shelly Kalaora, Eilon Barnea, Efrat Merhavi-Shoham, Nouar Qutob, Jamie K. Teer, Nilly Shimony, Jacob Schachter, Steven A. Rosenberg, Michal J. Besser, Arie Admon, Yardena Samuels

Research output: Contribution to journalArticle

Abstract

The antigenicity of cells is demarcated by the peptides bound by their Human Leucocyte Antigen (HLA) molecules. Through this antigen presentation, T cell specificity response is controlled. As a fraction of the expressed mutated peptides is presented on the HLA, these neo-epitopes could be immunogenic. Such neo-antigens have recently been identified through screening for predicted mutated peptides, using synthetic peptides or ones expressed from minigenes, combined with screening of patient tumor-infiltrating lymphocytes (TILs). Here we present a time and cost-effective method that combines whole-exome sequencing analysis with HLA peptidome mass spectrometry, to identify neo-antigens in a melanoma patient. Of the 1,019 amino acid changes identified through exome sequencing, two were confirmed by mass spectrometry to be presented by the cells. We then synthesized peptides and evaluated the two mutated neo-antigens for reactivity with autologous bulk TILs, and found that one yielded mutant-specific T-cell response. Our results demonstrate that this method can be used for immune response prediction and promise to provide an alternative approach for identifying immunogenic neo-epitopes in cancer.

Original languageEnglish (US)
Pages (from-to)5110-5117
Number of pages8
JournalOncotarget
Volume7
Issue number5
DOIs
StatePublished - 2016
Externally publishedYes

Fingerprint

Exome
HLA Antigens
Antigens
Peptides
Tumor-Infiltrating Lymphocytes
Epitopes
Mass Spectrometry
T-Cell Antigen Receptor Specificity
Antigen Presentation
Melanoma
T-Lymphocytes
Amino Acids
Costs and Cost Analysis
Neoplasms

Keywords

  • HLA
  • TILs

ASJC Scopus subject areas

  • Oncology

Cite this

Kalaora, S., Barnea, E., Merhavi-Shoham, E., Qutob, N., Teer, J. K., Shimony, N., ... Samuels, Y. (2016). Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens. Oncotarget, 7(5), 5110-5117. https://doi.org/10.18632/oncotarget.6960

Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens. / Kalaora, Shelly; Barnea, Eilon; Merhavi-Shoham, Efrat; Qutob, Nouar; Teer, Jamie K.; Shimony, Nilly; Schachter, Jacob; Rosenberg, Steven A.; Besser, Michal J.; Admon, Arie; Samuels, Yardena.

In: Oncotarget, Vol. 7, No. 5, 2016, p. 5110-5117.

Research output: Contribution to journalArticle

Kalaora, S, Barnea, E, Merhavi-Shoham, E, Qutob, N, Teer, JK, Shimony, N, Schachter, J, Rosenberg, SA, Besser, MJ, Admon, A & Samuels, Y 2016, 'Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens', Oncotarget, vol. 7, no. 5, pp. 5110-5117. https://doi.org/10.18632/oncotarget.6960
Kalaora S, Barnea E, Merhavi-Shoham E, Qutob N, Teer JK, Shimony N et al. Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens. Oncotarget. 2016;7(5):5110-5117. https://doi.org/10.18632/oncotarget.6960
Kalaora, Shelly ; Barnea, Eilon ; Merhavi-Shoham, Efrat ; Qutob, Nouar ; Teer, Jamie K. ; Shimony, Nilly ; Schachter, Jacob ; Rosenberg, Steven A. ; Besser, Michal J. ; Admon, Arie ; Samuels, Yardena. / Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens. In: Oncotarget. 2016 ; Vol. 7, No. 5. pp. 5110-5117.
@article{b1453427a0f646e9b2b086777e092b94,
title = "Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens",
abstract = "The antigenicity of cells is demarcated by the peptides bound by their Human Leucocyte Antigen (HLA) molecules. Through this antigen presentation, T cell specificity response is controlled. As a fraction of the expressed mutated peptides is presented on the HLA, these neo-epitopes could be immunogenic. Such neo-antigens have recently been identified through screening for predicted mutated peptides, using synthetic peptides or ones expressed from minigenes, combined with screening of patient tumor-infiltrating lymphocytes (TILs). Here we present a time and cost-effective method that combines whole-exome sequencing analysis with HLA peptidome mass spectrometry, to identify neo-antigens in a melanoma patient. Of the 1,019 amino acid changes identified through exome sequencing, two were confirmed by mass spectrometry to be presented by the cells. We then synthesized peptides and evaluated the two mutated neo-antigens for reactivity with autologous bulk TILs, and found that one yielded mutant-specific T-cell response. Our results demonstrate that this method can be used for immune response prediction and promise to provide an alternative approach for identifying immunogenic neo-epitopes in cancer.",
keywords = "HLA, TILs",
author = "Shelly Kalaora and Eilon Barnea and Efrat Merhavi-Shoham and Nouar Qutob and Teer, {Jamie K.} and Nilly Shimony and Jacob Schachter and Rosenberg, {Steven A.} and Besser, {Michal J.} and Arie Admon and Yardena Samuels",
year = "2016",
doi = "10.18632/oncotarget.6960",
language = "English (US)",
volume = "7",
pages = "5110--5117",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "5",

}

TY - JOUR

T1 - Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens

AU - Kalaora, Shelly

AU - Barnea, Eilon

AU - Merhavi-Shoham, Efrat

AU - Qutob, Nouar

AU - Teer, Jamie K.

AU - Shimony, Nilly

AU - Schachter, Jacob

AU - Rosenberg, Steven A.

AU - Besser, Michal J.

AU - Admon, Arie

AU - Samuels, Yardena

PY - 2016

Y1 - 2016

N2 - The antigenicity of cells is demarcated by the peptides bound by their Human Leucocyte Antigen (HLA) molecules. Through this antigen presentation, T cell specificity response is controlled. As a fraction of the expressed mutated peptides is presented on the HLA, these neo-epitopes could be immunogenic. Such neo-antigens have recently been identified through screening for predicted mutated peptides, using synthetic peptides or ones expressed from minigenes, combined with screening of patient tumor-infiltrating lymphocytes (TILs). Here we present a time and cost-effective method that combines whole-exome sequencing analysis with HLA peptidome mass spectrometry, to identify neo-antigens in a melanoma patient. Of the 1,019 amino acid changes identified through exome sequencing, two were confirmed by mass spectrometry to be presented by the cells. We then synthesized peptides and evaluated the two mutated neo-antigens for reactivity with autologous bulk TILs, and found that one yielded mutant-specific T-cell response. Our results demonstrate that this method can be used for immune response prediction and promise to provide an alternative approach for identifying immunogenic neo-epitopes in cancer.

AB - The antigenicity of cells is demarcated by the peptides bound by their Human Leucocyte Antigen (HLA) molecules. Through this antigen presentation, T cell specificity response is controlled. As a fraction of the expressed mutated peptides is presented on the HLA, these neo-epitopes could be immunogenic. Such neo-antigens have recently been identified through screening for predicted mutated peptides, using synthetic peptides or ones expressed from minigenes, combined with screening of patient tumor-infiltrating lymphocytes (TILs). Here we present a time and cost-effective method that combines whole-exome sequencing analysis with HLA peptidome mass spectrometry, to identify neo-antigens in a melanoma patient. Of the 1,019 amino acid changes identified through exome sequencing, two were confirmed by mass spectrometry to be presented by the cells. We then synthesized peptides and evaluated the two mutated neo-antigens for reactivity with autologous bulk TILs, and found that one yielded mutant-specific T-cell response. Our results demonstrate that this method can be used for immune response prediction and promise to provide an alternative approach for identifying immunogenic neo-epitopes in cancer.

KW - HLA

KW - TILs

UR - http://www.scopus.com/inward/record.url?scp=84958064376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958064376&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.6960

DO - 10.18632/oncotarget.6960

M3 - Article

VL - 7

SP - 5110

EP - 5117

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 5

ER -